Healthcare companies, which have grown manifold and provided significant support during the COVID-19 pandemic on both physical and virtual platforms, are looking to raise funds through capital markets.
This has prompted a shift to virtual care delivery, a focus on mental health and wellness, and rapid drug and vaccine candidate discovery.
Analysts said this would not have been possible without the contribution of new-age healthtech companies. From wellness and hospital groups to diagnostic services and bulk drugmakers, most are willing to go public.
Of the healthcare and pharma companies, 13 plan to raise approx. 21,000 crore through its initial public offering (IPO) through the market this year, according to data from research firm Prime Database.
These include Rainbow Children’s Medicare, Yatharth Hospital, Mediasist Healthcare Services, Scanray Technologies, Infineon Biopharma, Healthium Medtech, Vida Clinical Research, Sahajanand Medical Technologies, Global Health, GPT Healthcare, API Holdings, Kids Clinic India, Macleods Pharmaceuticals and Portea Medical.
“A lot of healthcare and pharma companies are raising money because their business is booming,” said Salil Kalianpour, former executive vice president of GlaxoSmithKline Plc.
12 healthcare companies picked up in less than a year 11,584 crores. These include Neureka, Krishna Institute of Medical Sciences, Tattva Chintan Pharma, Glenmark Life Sciences, Windlass Biotech, Krishna Diagnostics, Amy Organics, Vijaya Diagnostics, Sigachi Industries, Tarson Products, Medplus Health Services and Supriya Life Sciences. Most are trading at positive levels even after their listing.
HealthQuad, an India-focused healthcare venture capital firm, has raised $162 million. 1,215 crore) in the final closing of his second fund. The firm, which counts Medikabazaar, Ekincare, Healthifyme and Qure.ai in its portfolio of invested companies, has got global pharma maker MSD (Merck & Co., Inc.) as an anchor investor for the new fund.
Among the companies planning to go public, Chris Capital-backed Mankind Pharma has started preliminary discussions with investment bankers to launch a mega initial PU.
Blick Offering (IPO) in 2022. pharma company plans to raise approx 4,000 crores from the market according to development conscious people.
Kaliyanpour said that Mankind Pharma, which has a highly diversified portfolio, has an India-specific strategy, with good exposure in Tier-II and -III markets and a non-prescription-based portfolio, has proved to be very useful. .
He said that Mankind Pharma is now focusing on international development.
Analysts also pointed out that there are likely to be more healthtech IPOs and big-ticket mergers and acquisitions. Kalianpour said companies like PharmEasy are increasingly acquiring, collaborating with and building a complete platform for consumers, aiming to bring customers to a subscription-based model and make money overall. Is.
Another trend is that apart from traditional pharma companies, a lot of technology-driven health tech companies are booming. An analyst on the condition of anonymity said that many private equity players have shown interest in that sector.